CRISPR Therapeutics Director Rommel Christian Receives 13,000 Stock Options at $51.84 Exercise Price

CRISPR Therapeutics AG (CRSP) director Rommel Christian was granted 13,000 stock options on June 5, 2026, with an exercise price of $51.84 per share. The options have a 10-year term expiring on June 5, 2036. The grant represents a derivative transaction where Christian acquired the right to purchase common shares. The options will vest in 12 equal monthly installments starting June 30, 2026, subject to continued service with the company or its subsidiaries. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting. Following the transaction, Christian holds 13,000 stock options. The filing was signed by Elizabeth Ryland Waldinger on June 9, 2026.